Why the study?
Does marine n-3 PUFA improve cardiac autonomic and hemodynamic function in patients with psoriatic arthritis?
Does marine n-3 PUFA improve cardiac autonomic and hemodynamic function in patients with psoriatic arthritis?
Marine n-3 PUFA supplementation for 24 weeks improves heart rate variability and lowers resting heart rate in patients with psoriatic arthritis, suggesting a potential cardioprotective effect.
Supports n-3 PUFA for autonomic modulation in psoriatic arthritis; extends RCT evidence to inflammatory joint disease.
Background: Patients with psoriatic arthritis are at high cardiovascular risk.Marine n-3 polyunsaturated fatty acids (PUFA) may reduce the incidence of cardiovascular disease.The aim of this study was to investigate the effect of marine n-3 PUFA on cardiac autonomic function and vascular function in patients with psoriatic arthritis.Methods: The study was conducted as a randomized, double-blind, placebocontrolled trial, where 145 patients with psoriatic arthritis were supplemented with 3 g of n-3 PUFA or olive oil (control) daily for 24 weeks.Blood pressure, heart rate, HRV, central blood pressure, pulse wave velocity (PWV) and fatty acid composition of granulocytes, were determined.Results: At baseline we found a significant difference in the HRV parameter RR when comparing subjects with the highest vs the lowest fish intake (p Z 0.03).After supplementation for 24 weeks there was a trend towards an increase in RR (pZ 0.13) and decrease in heart rate (p Z 0.12) comparing the n-3 PUFA group with the control group.However, per-protocol analysis (performed on participants who completed the trial with a good compliance) showed significantly increased RR (p Z 0.01) and lowered heart rate (p Z 0.01) in the n-3 PUFA supplemented patients compared to controls.Blood pressure, PWV and central blood pressure did not change after supplementation with n-3 PUFA.Conclusions: Marine n-3 PUFA increased HRV in patients with psoriatic arthritis which may suggest a protective effect of n-3 PUFA against cardiovascular disease in this population. 7.
No takes yet. Share an insight, caveat, or question.
Kristensen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: